JANX
Janux Therapeutics, Inc.Company Information
- Company Name
- Janux Therapeutics, Inc.
- CIK
- CIK0001817713
- Category
- Large accelerated filer
- Ticker: Exchange
- JANX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- JANX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-03-07
- Last sale
- 2026-06-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 48,461
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 60,134,905
- Shares outstanding
- 62,937,295
- Ownership
- 95.55%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 11.99%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 28 | 52 | 52 | 48 | 52 | 74 | 431 | 27 | 15 | 213 | 19 | 17 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | 8 | 1 | - | - | ||||||
| Receivables Net Current | 0 | 35 | - | - | - | - | - | - | - | - | - | - | ||||||
| Short Term Investments | 943 | 905 | 914 | 941 | 944 | 940 | 595 | 631 | 632 | 439 | 325 | 333 | ||||||
| Prepaid Expense And Other Assets Current | 12 | 11 | 9 | 9 | 10 | 9 | 8 | 8 | 8 | 6 | 5 | 5 | ||||||
| Assets Current | 983 | 1,002 | 976 | 998 | 1,006 | 1,023 | 1,034 | 666 | 662 | 659 | 349 | 355 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 7 | 7 | 7 | ||||||
| Operating Lease Right Of Use Asset | 17 | 18 | 18 | 19 | 18 | 19 | 19 | 20 | 20 | 20 | 21 | 21 | ||||||
| Other Assets Noncurrent | 3 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | ||||||
| Assets | 1,008 | 1,028 | 1,002 | 1,025 | 1,032 | 1,051 | 1,062 | 695 | 691 | 689 | 380 | 387 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 3 | 5 | 3 | 3 | 2 | 4 | 2 | 1 | 2 | 2 | 3 | ||||||
| Accrued Liabilities Current | 20 | 15 | 18 | 22 | 16 | 13 | 12 | 13 | 9 | 6 | 7 | 7 | ||||||
| Contract With Customer Liability Current | 35 | 38 | - | - | - | - | 0 | 0 | 0 | 1 | 2 | 4 | ||||||
| Operating Lease Liability Current | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
| Liabilities Current | 60 | 59 | 25 | 28 | 21 | 18 | 17 | 17 | 12 | 11 | 13 | 14 | ||||||
| Contract With Customer Liability Noncurrent | 1 | 9 | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 18 | 19 | 20 | 20 | 20 | 21 | 21 | 22 | 22 | 23 | 23 | 23 | ||||||
| Liabilities | 80 | 87 | 45 | 48 | 42 | 38 | 39 | 39 | 34 | 33 | 36 | 38 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,328 | 1,317 | 1,304 | 1,291 | 1,282 | 1,270 | 1,258 | 866 | 849 | 840 | 512 | 507 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -2 | 1 | 4 | 5 | 4 | 4 | 2 | 8 | -2 | -1 | 1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -398 | -376 | -351 | -319 | -295 | -261 | -238 | -218 | -189 | -184 | -169 | -157 | ||||||
| Stockholders Equity | 928 | 942 | 957 | 977 | 991 | 1,012 | 1,023 | 656 | 658 | 656 | 344 | 349 | ||||||
| Liabilities And Stockholders Equity | 1,008 | 1,028 | 1,002 | 1,025 | 1,032 | 1,051 | 1,062 | 695 | 691 | 689 | 380 | 387 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 61 | 61 | 60 | 60 | 59 | 59 | 59 | 52 | 52 | 52 | 46 | 46 | ||||||
| Shares Outstanding | 61 | 61 | 60 | 60 | 59 | 59 | 59 | 52 | 52 | 52 | 46 | 46 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialJanux Therapeutics, Inc. (JANX) — SEC Financial Statements & Analysis
Janux Therapeutics, Inc. (JANX) is a pharmaceutical preparations company, incorporated in DE. Janux Therapeutics, Inc. trades on Nasdaq as: JANX. Janux Therapeutics, Inc. (JANX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Janux Therapeutics, Inc. carries a market cap of $966.72M, a P/E ratio of -9.42x, a P/B ratio of 1.04x, a P/S ratio of 40.28x, an enterprise value of $938.95M, and an EV/EBITDA multiple of -6.63x. On profitability, it posts an operating margin of -598.15%, a net margin of -427.47%, a Return on Equity (ROE) of -10.70%, a Return on Assets (ROA) of -10.06%, and a Return on Invested Capital (ROIC) of -15.61%. Per share, it reports EPS of $-1.63, diluted EPS of $-1.63, free cash flow per share of $-0.67, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 5366.97% year-over-year, net income growth of -2.89% year-over-year, and EPS growth of -4.48% year-over-year. On the balance sheet, it maintains a current ratio of 16.35x, a quick ratio of 16.14x, working capital of $923.18M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-41.92M (TTM), and net debt of $-27.77M. Figures sourced from SEC EDGAR.
- Market Cap
- $966.72M
- P/E TTM
- -9.42x
- EPS TTM
- $-1.63
- P/B TTM
- 1.04x
- ROE TTM
- -10.70%
- ROA TTM
- -10.06%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-41.92M
- Net Revenue TTM Growth 1Y
- 5366.97%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Janux Therapeutics, Inc. in?
Janux Therapeutics, Inc. (JANX) operates in the Pharmaceutical Preparations industry.
What exchange does JANX trade on?
Janux Therapeutics, Inc. (JANX) trades on the Nasdaq.
Where is Janux Therapeutics, Inc. incorporated?
Janux Therapeutics, Inc. is incorporated in DE.
When was Janux Therapeutics, Inc. (JANX)'s most recent SEC filing?
Janux Therapeutics, Inc. (JANX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is JANX's market cap?
Janux Therapeutics, Inc. (JANX) has a market capitalization of $966.72M as of 2026-06-30.
What is JANX's EPS (earnings per share)?
Janux Therapeutics, Inc. (JANX)'s trailing twelve month EPS is $-1.63 as of 2026-06-30.
What is JANX's ROE (return on equity)?
Janux Therapeutics, Inc. (JANX)'s trailing twelve month Return on Equity (ROE) is -10.70% as of 2026-06-30.
What is JANX's ROA (return on assets)?
Janux Therapeutics, Inc. (JANX)'s trailing twelve month Return on Assets (ROA) is -10.06% as of 2026-06-30.
What is JANX's ROIC (return on invested capital)?
Janux Therapeutics, Inc. (JANX)'s trailing twelve month Return on Invested Capital (ROIC) is -15.61% as of 2026-06-30.
What is JANX's EV/EBITDA?
Janux Therapeutics, Inc. (JANX)'s trailing twelve month EV/EBITDA is -6.63x as of 2026-06-30.